Impostor sends phony CEO email, tricks healthcare provider into releasing employee data

A rehabilitation and nursing home healthcare provider in California has announced it mistakenly sent employee information to someone impersonating its CEO via email.

Magnolia Health Corporation (MHC) said it released a spreadsheet containing the names, addresses, dates of birth, social security numbers, salary information and other employment details of every active MHC employee in response to an email originally believed to be sent from company CEO Kenny Moyle on Feb. 3.

A week later, it was discovered that no such request was made by Moyle, causing MHC to alert its employees to the information breach.

“We have reported this matter to law enforcement,” the company said in a letter to all employees, “and we are taking steps to ensure that no unauthorized disclosures will occur in the future.”

Those steps include providing fraud monitoring assistance and complimentary identity theft prevention services for all MHC employees.

While the perpetrator behind the incident has yet to be identified, the company said it will continue to work with local authorities “to learn the identity of the individual(s) responsible so that they can be prosecuted to the fullest extent of the law.”  

Read the full announcement here.

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.